Paolo M. Comoglio

Medicine · Health Sciences

115h-index45.7kcitations751works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver physiology and pathology(267), Cancer Research and Treatments(73), PI3K/AKT/mTOR signaling in cancer(72), Fibroblast Growth Factor Research(58), Colorectal Cancer Treatments and Studies(56)

Publications751 total

The integrated stress response drives MET oncogene overexpression in cancers
The EMBO Journal·2025· 10 citedOpen Access
An Observatory for the MET Oncogene: A Guide for Targeted Therapies
Cancers·2023· 7 citedOpen Access
Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomas
Cell Reports·2023· 12 citedOpen Access
Supplementary Figure S4 from Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
2023Open Access
Supplementary Figure 5 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Figure 1 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Figure 5 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Figure 6 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Table 1 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Figure S3 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023Open Access
Supplementary Table S1 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023Open Access
Supplementary Table 2 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Data from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023Open Access
Data from Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
2023Open Access
Supplementary Figure 2 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Figure 3 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Figure S5 from Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
2023Open Access
Supplementary Table 1 from A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
2023Open Access
Supplementary Figure S3 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023Open Access
Supplementary Figure S1 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
2023Open Access
page 1 of 38Next →

Frequent Co-authors

Silvia Giordano(14), Livio Trusolino(10), Luca Tamagnone(9), Luigi Naldini(8), Alberto Bardelli(8), Maria Flavia Di Renzo(6), Simona Corso(6), Carla Boccaccio(6), Martina Olivero(5), Andrea Bertotti(5), Enzo Médico(5), Carola Ponzetto(4), Francesco Galimi(4), Giovanni Gaudino(3), Paolo Michieli(3), Andrea Sartore‐Bianchi(3), Emanuele Valtorta(3), Salvatore Siena(3), Elisa Vigna(3), Radha P. Narsimhan(3)